As a natural metabolite and Nrf2 agonist, itaconate inhibits the initiation and progression of fibrosis by activating multiple downstream protective proteins via Nrf2, suggesting that itaconate could serve as a novel endogenous antifibrotic agent in the treatment of IPF. Here, NFE2L2 is linked to idiopathic pulmonary fibrosis.